Anti-cancer compounds

Details Anti-cancer compounds Anti-cancer compounds

2008-09-17

2010-12-28

Kam, Chih-Min (Department: 1656)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Preparing alpha or beta amino acid or substituted amino acid...

C435S117000, C435S007100, C424S009100, C562S433000, C530S300000, C530S314000, C530S333000, C530S402000

Reexamination Certificate

active

07858349

ABSTRACT:
The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.

REFERENCES:
patent: 3235594 (1966-02-01), Levi et al.
patent: 4904680 (1990-02-01), Matsui et al.
patent: 5635593 (1997-06-01), Cheronis et al.
patent: 5849863 (1998-12-01), Stewart
patent: 6388054 (2002-05-01), Stewart et al.
patent: 7071168 (2006-07-01), Stewart et al.
patent: 7427496 (2008-09-01), Stewart et al.
patent: WO 97/09347 (1997-03-01), None
D. Chan, et al., “Novel bradykinin antagonist dimers for the treatment of human lung cancers,” Immunopharmacology, vol. 33, 1996, pp. 201-204.
L. Gera, et al., “New Bradykinin Antagonists Having High Potency at Both B1 and B2 Receptors,” Peptides: Chemistry, Structure and Biology, Mayflower Scientific Ltd., 1996, pp. 348-349.
Stewart et al., Can. J. Physiol. Pharmacol. 75:719-724, 1997.
International Search Report for International (PCT) Patent Application No. PCT/US99/19381, mailed Feb. 10, 2000.
Written Opinion for International (PCT) Patent Application No. PCT/US99/19381, mailed Oct. 5, 2000.
International Preliminary Examination Report for International (PCT) Patent Application No. PCT/US99/19381, mailed Apr. 24, 2001.
Bawolak MT, Gera L, Morissette G, Stewart JM, Marceau F. B-9972 (D-Arg-[Hyp(3), Igl(5),Oic(7), Igl(8)]-bradykinin) is an inactivation-resistant agonist of the bradykinin B-2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp(3), Igl(5), D-Igl(7), Oic(8)]-bradykinin): Pharmacologic profile and effective induction of receptor degradation. Journal of Pharmacology and Experimental Therapeutics 323 (2): 534-546, 2007.
Morissette G, Houle S, Gera L, Stewart JM, Marceau F. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B-1 and B-2 receptors. British Journal of Pharmacology 150 (3): 369-379 Feb. 2007.
Larrivee JF, Gera L, Houle S, Bouthillier J, Bachvarov DR, Stewart JM, Marceau F. Non-competitive pharmacological antagonism at the rabbit B-1 receptor. British Journal of Pharmacology, 131 (5): 885-892,2000.
Gera L, Fortin JP, Adam A, Stewart JM, Marceau F. Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B-1 receptor antagonism. Journal of Pharmacology and Experimental Therapeutics, 317 (1): 300-308, 2006.
Inamura et al., “Characterization of FR173657, a novel, non-peptide BK2 antagonist, in vitro and in vivo”, Can. J. Physiol. Pharmacol. 75, 622-628 (1997).
L. Gera at al., A new class of potent bradykinin antagonist dimers. Immunopharmacology (1996), 33(1-3), 178-82.
L. Gera and JM. Stewart, A new class of bradykinin antagonists containing indanylglycine. Immunopharmacology (1996), 33(1-3), 174-77.
Griesbacher et al. “The nonpeptide B2 receptor antagonist FR173657: inhibition of effects of bradykinin related to its role in nociception” British Journal of Pharmacology (1998) 124, 1328-1334.

Affiliated with

Also associated with

Rating

Anti-cancer compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4204833